On the way to specifically targeting minimal residual disease?

Area of Science:

• Oncology
• Cancer Biology
• Translational Research

Background:

• Adjuvant systemic therapies in breast cancer target minimal residual disease (MRD) post-surgery.
• Tumor cell dissemination occurs early, but the biology of these residual cells remains largely unknown.
• Current patient selection for endocrine therapy relies on primary tumor receptor analysis, which may not reflect disseminated cell characteristics.

Discussion:

• Investigating the tumor biology of disseminated cells is crucial for optimizing adjuvant therapies.
• Understanding receptor expression variability between primary and residual tumors is essential.
• This knowledge gap impacts the efficacy of targeted treatments for minimal residual disease.

Key Insights:

• Residual tumor cells may exhibit different biological parameters, including receptor expression, compared to the primary tumor.
• Discrepancies in receptor expression can affect the effectiveness of adjuvant endocrine therapies.
• Early-stage tumor cell dissemination necessitates a deeper understanding of residual disease biology.

Outlook:

• Future research should focus on characterizing disseminated tumor cells to refine patient stratification.
• Developing methods to analyze residual cell characteristics could improve treatment selection.
• Enhanced understanding will guide the development of more effective adjuvant strategies against breast cancer recurrence.